Introduction of Midkine Gene into Human Bladder Cancer Cells Enhances Their Malignant Phenotype but Increases Their Sensitivity to Antiangiogenic Therapy

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5152-5160

  Muramaki, Mototsugu ^a   Miyake, Hideaki ^b   Hara, Isao ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GENE PRODUCT; MIDKINE;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER CONTROL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MIDKINE GENE; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CARRIER PROTEINS; CELL DIVISION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CYCLOHEXANES; CYTOKINES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; SESQUITERPENES; TRANSFECTION; TUMOR CELLS, CULTURED; UMBILICAL VEINS; URINARY BLADDER NEOPLASMS;

EID: 0242442033     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Thurman, S. A., and DeWeese, T. L. Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin. Urol. Oncol., 18: 313-322, 2000.
2. Vaughn, D. J., and Malkowicz, S. B. Recent advances in bladder cancer chemotherapy. Cancer Investig., 19: 77-85, 2001.
3. Juffs, H. G., Moor, M. J., and Tannock, I. F. The role of systemic chemotherapy in the management of muscle-invasive bladder cnacer. Lancet Oncol., 3: 738-747, 2002.
4. Tomomura, M., Kadomatsu, K., Matsubara, S., and Muramatsu, T. A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. J. Biol. Chem., 265: 10765-10770, 1990.
5. Kadomatsu, K., Huang, R., Suganuma, T., Murata, F., and Muramatsu, T. A retinoic acid responsive gene, MK, found in the teratocarcinoma system is expressed in a spatially and temporally controlled manner during mouse embryogenesis. J. Cell Biol., 110: 607-616, 1990.
6. Kojima, S., Imui, T., Muramatsu, H., Kimura, T., Sakakiba, S., and Muramatsu, T. Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem. Biophys. Res. Commun., 216: 574-581, 1995.
7. Kadomatsu, K., Hagihara, M., Akhter, S., Fan, Q-W., Muramatsu, H., and Muramatsu, T. Midkine induces the transformation of NIH3T3 cells. Br. J. Cancer, 75: 354-359, 1997.
8. Owada, K., Sanjo, N., Kobayashi, T., Mizusawa, H., Muramatsu, T., and Michikawa, M. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J. Neurochem., 73: 2084-2092, 1999.
9. Choudhuri, R., Zang, H. T., Donnini, S., Ziche, M., and Bicknell, R. An angiogenic role for the neurokines midkine and pleiotropin in tumorigenesis. Cancer Res., 57: 1814-1819, 1997.
10. Miyauchi, M., Shimada, H., Kadomatsu, K., Muramatsu, T., Matsubara, S., and Tagawa, M. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn. J. Cancer Res., 90: 469-475, 1999.
11. Aridome, K., Tsutsui, J., Takao, S., Kadomatsu, K., Ozawa, M., Akiou, T., and Muramatsu, T. Increased midkine gene expression in human gastrointestinal cancers. Jpn. J. Cancer Res., 86: 655-661, 1995.
12. Muramatsu, T., and Kadomatsu, K. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br. J. Cancer, 79: 179-184, 1999.
13. Muramatsu, T., and Yamamura, K. The expression of truncated MK in human tumors. Biochem. Biophys. Res. Commun., 219: 256-260, 1996.
14. Graver, R. I., Jr., Chan, C. S., and Milner, P. G. Reciprocal expression of pleiotropin and midkine in normal versus malignant lung tissues. Am. J. Respir. Cell Mol. Biol., 9: 463-466, 1993.
15. Graver, R. I., Jr., Radford, D. M., Domis-Keller, H., Wick, M. R., and Milner, P. G. Midkine and pleiotropin expression in normal and malignant breast tissue. Cancer (Phila.), 74: 1584-1590, 1994.
16. O'Brien, T., Canston, D., Fuggle, S., Bicknell, R., and Harris, A. L. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res., 56: 2515-2518, 1996.
17. Plate, K. H., Breier, G., and Risau, W. Molecular mechanism of development and tumor angiogenesis. Brain Pathol., 4: 207-218, 1994.
18. Hanahan, D., and Folkman, J. Pattern and emerging mechanism of the angiogenetic switch during tumorigenesis. Cell, 86: 353-364, 1996.
19. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D., and Bigler, S. A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (Phila.), 73: 678-687, 1994.
20. Delahunt, B., Bethwaite, P. B., and Thornton, A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br. J. Urol., 80: 401-404, 1997.
21. Bochner, B. H., Cote, N. W., Groshen, S., Chen, S., Skinner, D. G., and Nichols, P. W. Angiogenesis in bladder cancer; relationship between microvessl density and tumor prognosis. J. Natl. Cancer Inst. (Bethesda), 87: 1603-1612, 1995.
22. Allen, L. E., and Maher, P. A. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J. Cell Physiol., 155: 368-375, 1993.
23. Brown, L. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.
24. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. N., and Harris, A. L. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol., 74: 762-766, 1994.
25. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., Dunn, M., Nichols, P. W., Taylor, C. R., Skinner, D. G., and Core, R. Thrombospondin-1 expression in bladder cancer: association with p53 alternations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst. (Bethesda), 89: 219-227, 1997.
26. Sumi, Y., Muramatsu, H., Takei, Y., Hata, K., Ueda, M., and Muramatsu, T. Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J. Cell Sci., 115: 2659-2667, 2002.
27. Streeter, E. H., and Harris, A. L. Angiogenesis in bladder cancer: prognostic marker and target for future therapy. Surg. Oncol., 11: 85-100, 2002.
28. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamatsu, T., Brem, H., and Folkman, J. Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.), 348: 555-557, 1990.
29. Murai, S., Itoh, F., Kozai, Y., Sudo, K., and Kishimoto, S. Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols. Chem. Pharm. Bull. (Tokyo), 40: 96-101, 1992.
30. Fujioka, T., Hasegawa, M., Ogiu, K., Matsushita, Y., Sato, M., and Kubo, T. Antitumor effects of angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagilloll (TNP-470) against murine renal cell carcinoma. J. Urol., 155: 1775-1778, 1996.
31. Kanai, T., Konno, H., Tanaka, T., Matsumoto, K., Baba, M., Nakamura, S., and Baba, S. Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. Int. J. Cancer, 71: 838-841, 1997.
32. Tanaka, T., Konno, H., Matsuda, I., Nakamura, S., and Baba, S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res., 55: 836-839, 1995.
33. Yanase, T., Tamura, M., Hujita, K., Kodama, S., and Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res., 53: 2566-2570, 1993.
34. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Hujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53: 5233-5236, 1993.
35. Tanaka, Y., Kawamata, H., Hujimoto, K., and Oyasu, R. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J. Urol., 157: 683-688, 1997.
36. Beecken, W. D., Fernandez, A., Panigrahy, D., Achilles, E. G., Kisker, O., Flynn, E., Joussen, A. M., Folkman, J., and Shing, Y. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology, 56: 521-526, 2000.
37. Miyake, H., Yoshimura, K., Hara, I., Eto, H., Arakawa, S., and Kamindono, S. Basic fibroblast growth factor regulates matrix mettaloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J. Urol., 157: 2351-2355, 1997.
38. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
39. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 47: 3239-3245, 1987.
40. Gehlsen, K. R., Davis, G. E., and Sriramarao, P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin. Exp. Metastasis, 10: 111-120, 1992.
41. Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S., and Kamidono, S. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br. J. Cancer, 79: 1651-1656, 1999.
42. Beckstead, J. H. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J. Histochem. Cytochem., 42: 1127-1134, 1994.
43. Fox, S. B., Leek, R. D., Weeks, M. P., Whitehouse, R. M., Gatter, K. C., and Harris, A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J. Pathol., 177: 275-283, 1995.
44. Philp, E. A., Stephenson, T. J., and Reed, M. W. R. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder. Br. J. Urol., 77: 352-357, 1996.
45. Jeager, T. M., Weidner, N., Chew, K., Moore, D. H., Kerschmann, R. L., Waldman, F. M., and Carroll, P. R. Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer. J. Urol., 154: 69-71, 1995.
46. Hawke, C. K., Delahunt, B., and Davidson, P. J. T. Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder. Br. J. Urol., 81: 585-590, 1998.
47. Beecken, W. D., Kramer, W., and Jonas, D. New molecular mediators in tumor angiogenesis. J. Cell. Mol. Med., 4: 262-269, 2000.
48. Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kagawa, K., Shioi, A., and Morii, H. The fumagillin analogue TNP470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Possible involvement of cyclin-dependent kinase 2. Circ. Res., 9: 754-764, 1996.
49. Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res., 54: 3407-3412, 1994.
50. Ma, J., Pulfer, S., Li, S., Chu, J., Reed, K., and Gallo, J. M. Pharmacodynamic-mediated reduction of temozolomide tumor concentration by the angiogenesis inhibitor TNP-470. Cancer Res., 61: 5491-5498, 2001.
51. Inoue, K., Chikazawa, M., Fukata, S., Yoshikawa, C., and Shun, T. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin. Cancer Res., 8: 2389-2398, 2002.
52. Zhang, X., Yamashita, M., Uetsuki, H., and Kakei, Y. Short-term effects of TNP-470 in combination with cisplatin in the rat model of bladder cancer. In Vivo, 16: 293-298, 2002.